| Identification | Back Directory | [Name]
BMS-911543 | [CAS]
1271022-90-2 | [Synonyms]
CS-785
BMS-911543
BMS911543;BMS 911543
N,N-Dicyclopropyl-4-((1,5-dimethyl-1H-pyrazol-3-yl)amino)-6-ethyl-1-methyl-1,6-dihydroimidazo[
N,N-Dicyclopropyl-4-((1,5-dimethyl-1H-pyrazol-3-yl)amino)-6-ethyl-1-methyl-1,6-dihydroimidazo[4,5-d]pyrrolo[2,3-b]pyridine-7-carboxamide
N,N-Dicyclopropyl-4-[(1,5-dimethyl-1H-pyrazol-3-yl)amino]-6-ethyl-1,6-dihydro-1-methyl-imidazo[4,5-d]pyrrolo[2,3-b]pyridine-7-carboxamide
Imidazo[4,5-d]pyrrolo[2,3-b]pyridine-7-carboxamide, N,N-dicyclopropyl-4-[(1,5-dimethyl-1H-pyrazol-3-yl)amino]-6-ethyl-1,6-dihydro-1-methyl- | [EINECS(EC#)]
1308068-626-2 | [Molecular Formula]
C23H28N8O | [MDL Number]
MFCD22200575 | [MOL File]
1271022-90-2.mol | [Molecular Weight]
432.52 |
| Chemical Properties | Back Directory | [storage temp. ]
Keep in dark place,Inert atmosphere,2-8°C | [solubility ]
≥43.3 mg/mL in DMSO with gentle warming; insoluble in H2O; ≥9.8 mg/mL in EtOH with gentle warming and ultrasonic | [form ]
Powder | [color ]
White to light yellow |
| Hazard Information | Back Directory | [Uses]
BMS 911543 is a functionally selective small molecule inhibitor of JAK2 and have been developed as a treatment for leukemia. | [Biological Activity]
bms-911543 is a selective small-molecule inhibitor of jak2 with ic50 value of 1.1nm [1].bms-911543 is a reversible pyrrolopyridine atp-competitive jak2 inhibitor with a high selectivity. in the in vitro assay using human recombinant jak enzyme, bms-911543 displays an ic50 value of 1.1nm against jak2 and the ki value is 0.48nm. the inhibition activity and affinity against jak2 are both much higher than those against jak1 and jak3. besides that, bms-911543 also has efficacy against other kinases, such as lyn and the c-fms receptor tyrosine kinase. in jak-dependent cells such as set2 or ba/f3, the treatment of bms-911543 causes an anti-proliferative effect with ic50 values of 60 and 70nm, respectively. the cell lines depending on other jak family members do not show significant anti-proliferative response to bms-911543. the colony growth assays prove that bms-911543 can suppress the growth of mpn patient-derived cells and is more potent in the jak2v617f pathway compared with the jak2wt pathway. bms-911543 is also found to be potent in vivo in both the jak2wt pathway and the jak2v617f pathway through suppressing pstat5 induction [1]. | [in vivo]
BMS-911543 is well tolerated up to 100 mg/kg in rats (mean AUC0-72 h, 11300 μM·h) and dogs (AUC0-24 h, 610 μM·h). A 15 mg/kg/day dose (Day 14 AUC0-24 h, 3200 μM·h) is well tolerated[1] in two-week repeat dose studies in rats. BMS-911543 (30 mg/kg, p.o.) suppresses the growth of tumor and prolongs the median survival in KPC-Brca1 mice. BMS-911543 also selectively reduces pSTAT5 expression in pancreatic tumors and decreases levels of intratumoral FoxP3+ T regulatory cells in mice administered BMS-911543[2]. | [target]
JAK2 | [IC 50]
JAK2: 1.1 nM (IC50); Tyk2: 66 nM (IC50); JAK1: 75 nM (IC50); JAK3: 360 nM (IC50) | [References]
[1] purandare av, mcdevitt tm, wan h, you d, penhallow b, han x, vuppugalla r, zhang y, ruepp su, trainor gl, lombardo l, pedicord d, gottardis mm, ross-macdonald p, de silva h, hosbach j, emanuel sl, blat y, fitzpatrick e, taylor tl, mcintyre kw, michaud e, mulligan c, lee fy, woolfson a, lasho tl, pardanani a, tefferi a, lorenzi mv. characterization of bms-911543, a functionally selective small-molecule inhibitor of jak2. leukemia. 2012 feb;26(2):280-8. |
|
| Company Name: |
NCE Biomedical Co.,Ltd.
|
| Tel: |
4000-027-021 |24 +86-13986109188 | +86-15623472865 | +81-08033611988 |
| Website: |
www.chemicalbook.com/ShowSupplierProductsList15748/0_EN.htm |
|